Piper Sandler raised the firm’s price target on Evolent Health (EVH) to $18 from $16 and keeps an Overweight rating on the shares ahead of investor meetings with the company’s CFO. The firm cites first half of 2025 execution and as it rolls its unchanged 15-times multiple forward to 2026 adjusted EBITDA due to the passage of time.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health Closes $166.75M Convertible Notes Sale
- Evolent Health Upsizes Convertible Notes Offering
- Evolent Health prices upsized $145M convertible senior note debt
- Closing Bell Movers: Palo Alto Networks jumps 5% on Q4 earnings beat
- Evolent Health announces $140M convertible senior notes offering